Carbamazepine polymorphism: a re-visitation using Raman imaging

Abstract

Raman imaging methods have appeared in the last years as a powerful approach to monitoring the quality of pharmaceutical compounds. Because polymorphism occurs in many crystalline pharmaceutical compounds, it is essential to monitor polymorphic transformations induced by different external stimulus, such as temperature changes, to which those compounds may be submitted. Raman imaging with k-means cluster analysis (CA) is used here as an essential technique to investigate structural and chemical transformations occurring in carbamazepine p-monoclinic (CBZ III) into carbamazepine triclinic (CBZ I) when submitted to temperatures near the melting point of CBZ III (178 °C) and CBZ I (193 °C). CBZ III commercial powder and laboratorial prepared CBZ I were analyzed by differential scanning calorimetry, powder X-ray diffraction and Raman spectroscopy with variable temperature. After thermal treatment, the resultant CBZ powder was evaluated by Raman imaging, in which all imaging data was analyzed using CA. Raman imaging allowed the identification of different polymorphs of CBZ (CBZ III and CBZ I) and iminostilbene (IMS), a degradation product of CBZ, in the treated samples, depending on the heating treatment method.